Study: no evidence of bias in commercial CME

An analysis of CME data by two Cleveland Clinic Foundation physicians found little evidence of perceived bias in CME activities.

Their report, published in the January edition of the Association of American Medical Colleges' journal Academic Medicine and entitled “The effect of industry support on participants' perceptions of bias in continuing medical education,” aimed to “obtain prospective evidence of whether industry support of continuing medical education affects perceptions of commercial bias in CME activities.”

The conclusion? “This large, prospective analysis found no evidence that commercial support results in perceived bias in CME activities. Bias level seem quite low for all types of CME activities and is not significantly higher when commercial support is present.”

According to the report, the authors found, when asked “Overall, was this activity satisfactorily free from commercial bias,” between 97.3% to 99.2% of participants answered affirmatively. When asked to rate the degree to which the activity met ACCME requirements that activities be free of commercial bias for or against a product, 95.8% to 99.3% answered “good” or “excellent.”

The authors analyzed information from the 2007 CME activity database of a large, multispecialty academic medical center including 346 activities of various types and 95,429 participants.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.